The planned expansion will expand the capacity of the Charles River Accelerator and Development Lab (CRADL).
Charles River Laboratories announced a planned expansion of the Charles River Accelerator and Development Lab (CRADL) in Cambridge, Mass., on Oct. 20, 2021. In addition to a 30,000 ft² expansion to its existing facilities on Binney Street, a new 18,000 ft² location is being planned.
CRADL is a ready-to-use vivarium rental space used in various animal studies that is intended to eliminate concerns of animal husbandry and daily vivarium management. CRADL also provides access to Charles River’s existing portfolio of in-vivo support services such as transgenic model creation, animal health surveillance, and more.
“In the biopharmaceutical industry, both infrastructure and staffing can be prohibitively expensive and take significant time to develop,” said Julie Freebersyser, director of CRADL operations at Charles River, in a company press release. “CRADL alleviates that burden by providing best-in-class vivarium space and management to both emerging and established institutions. By outsourcing their vivarium space, researchers can focus on research, instead of logistics.”
Source: Charles River
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.